---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-002873"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2022-03-04T23:59:59+00:00"
generated_at: "2026-06-27T01:36:41.564668+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics CSO David Dornan resigns, stays as consultant for 6 months

## Summary
- David Dornan, Ph.D. resigned as Chief Scientific Officer effective March 11, 2022.
- Entered consulting agreement for 6 months at $500/hour to assist transition.
- Outstanding equity awards will continue to vest during consulting period.
- Consultant reports to CEO Randall Schatzman.

## SEC filing metadata
- accession: 0000950170-22-002873
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2022-03-04T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017022002873/0000950170-22-002873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017022002873/bolt-20220301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-002873
- JSON: https://secwatch.observer/filing/0000950170-22-002873.json
- Plain text: https://secwatch.observer/filing/0000950170-22-002873.txt

## Key facts
- Executive change
  David Dornan resigned as Chief Scientific Officer at Bolt Biotherapeutics, Inc..
  - Action: resigned
  - Role: Chief Scientific Officer
  source text: On March 1, 2022, David Dornan, Ph.D. notified Bolt Biotherapeutics, Inc. of his resignation as our Chief Scientific Officer, effective March 11, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000095017022002873/0000950170-22-002873-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.